Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af målrettede terapier til behandling af voksne deltagere med aktiv psoriasis arthritis

5. november 2026 opdateret af: AbbVie

En fase 2 -multicenter, randomiseret platformundersøgelse af målrettede terapier til behandling af voksne individer med aktiv psoriasisartrit

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.

The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

300

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Quebec
      • Sherbrooke, Quebec, Canada, J1G 2E8
        • Rekruttering
        • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
      • Trois-Rivières, Quebec, Canada, G9A 3X2
        • Rekruttering
        • Centre de Recherche Musculo-Squelettique /ID# 274397
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7H 0P4
        • Rekruttering
        • Dr. Latha Naik Medical Professional Corporation /ID# 272803
    • California
      • Huntington Beach, California, Forenede Stater, 92648-5994
        • Rekruttering
        • Newport Huntington Medical Group /ID# 272764
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 714-923-7112
    • Florida
      • Avon Park, Florida, Forenede Stater, 33825
        • Rekruttering
        • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 863-314-8555
      • Clearwater, Florida, Forenede Stater, 33765
        • Rekruttering
        • Clinical Research Of West Florida - Phase I Unit /ID# 273198
      • Orlando, Florida, Forenede Stater, 32819
        • Rekruttering
        • HMD Research LLC /ID# 273086
      • Tamarac, Florida, Forenede Stater, 33321
        • Rekruttering
        • West Broward Rheumatology Associates /ID# 272892
      • Tampa, Florida, Forenede Stater, 33606
        • Rekruttering
        • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: (813) 870-1292
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
      • Skokie, Illinois, Forenede Stater, 60076
        • Afsluttet
        • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
      • Willowbrook, Illinois, Forenede Stater, 60527
        • Rekruttering
        • Willow Rheumatology and Wellness /ID# 277354
    • Maryland
      • Cumberland, Maryland, Forenede Stater, 21502
        • Afsluttet
        • Klein & Associates /ID# 272829
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater, 03756
        • Rekruttering
        • Dartmouth-Hitchcock Medical Center /ID# 272702
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 603-650-4717
    • Ohio
      • Middleburg Heights, Ohio, Forenede Stater, 44130
        • Rekruttering
        • Paramount Medical Research and Consulting /ID# 272757
    • Pennsylvania
      • Duncansville, Pennsylvania, Forenede Stater, 16635
        • Rekruttering
        • Altoona Center For Clinical Research /ID# 272593
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 814-296-6108
    • Tennessee
      • Memphis, Tennessee, Forenede Stater, 38119
        • Rekruttering
        • Private Practice - Dr. Ramesh C. Gupta /ID# 272897
    • Texas
      • Austin, Texas, Forenede Stater, 78745
        • Rekruttering
        • Tekton Research - West Gate /ID# 272765
      • Frisco, Texas, Forenede Stater, 75035
        • Rekruttering
        • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
      • Houston, Texas, Forenede Stater, 77089-6142
        • Rekruttering
        • Accurate Clinical Research - Houston /ID# 272754
      • San Antonio, Texas, Forenede Stater, 78251
        • Rekruttering
        • Tekton Research, LLC /ID# 272901
      • Tomball, Texas, Forenede Stater, 77375
        • Rekruttering
        • DM Clinical Research - Tomball /ID# 272760
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Frankrig, 06001
        • Rekruttering
        • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
    • Auvergne-Rhône-Alpes
      • Caluire-et-Cuire, Auvergne-Rhône-Alpes, Frankrig, 69300
        • Rekruttering
        • Infirmerie Protestante De Lyon /ID# 273731
    • Indre-et-Loire
      • Chambray-lès-Tours, Indre-et-Loire, Frankrig, 37170
        • Rekruttering
        • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
    • Loiret
      • Orléans, Loiret, Frankrig, 45067
        • Afsluttet
        • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrig, 33076
        • Afsluttet
        • Chu Bordeaux - Hopital Pellegrin /ID# 273390
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-068
        • Rekruttering
        • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
    • Masovian Voivodeship
      • Pruszków, Masovian Voivodeship, Polen, 05-800
        • Rekruttering
        • MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
      • Warsaw, Masovian Voivodeship, Polen, 02-665
        • Rekruttering
        • Centrum Medyczne Reuma Park /ID# 273301
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polen, 15-351
        • Afsluttet
        • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
    • Warmian-Masurian Voivodeship
      • Elblag, Warmian-Masurian Voivodeship, Polen, 82-300
        • Afsluttet
        • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
      • Uherské Hradiště, Tjekkiet, 686 01
        • Rekruttering
        • Medical Plus Research /ID# 272363
      • Zlín, Tjekkiet, 760 01
        • Rekruttering
        • PV Medical Services /ID# 272368
    • Brno-mesto
      • Brno, Brno-mesto, Tjekkiet, 638 00
        • Rekruttering
        • Revmatologie /ID# 272367
    • Moravian-Silesian Region
      • Hlučín, Moravian-Silesian Region, Tjekkiet, 748 01
        • Rekruttering
        • L.K.N. Arthrocentrum /ID# 272366
      • Budapest, Ungarn, 1027
        • Rekruttering
        • Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
      • Budapest, Ungarn, 1023
        • Rekruttering
        • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
    • Borsod-Abauj Zemplen county
      • Miskolc, Borsod-Abauj Zemplen county, Ungarn, 3529
        • Rekruttering
        • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
    • Fejér
      • Székesfehérvár, Fejér, Ungarn, 8000
        • Rekruttering
        • Complex Rendelo Med Zrt. /ID# 272570
      • Veszprém, Fejér, Ungarn, 8200
        • Rekruttering
        • Vital-Medicina /ID# 272855

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
  • Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
  • Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
  • Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
  • Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria:

  • Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
  • Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
  • Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Substudy 1: Risankizumab Monotherapy

Participants will receive risankizumab

Subcutaneous (SC) Injection

Eksperimentel: Substudy 1: Lutikizumab Monotherapy

Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week.

Subcutaneous (SC) Injection

Eksperimentel: Substudy 1: Lutikizumab and Risankizumab Combination Therapy

Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

Eksperimentel: Substudy 2: ABBV-701 Monotherapy

Participants will initially receive ABBV-701.

Subcutaneous (SC) Injection

Eksperimentel: Substudy 2: Risankizumab Monotherapy

Participants will receive risankizumab.

Subcutaneous (SC) Injection

Eksperimentel: Substudy 2: ABBV-701 and Risankizumab Combination Therapy

Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

Eksperimentel: Substudy 3: ABBV-547 Dose A

Participants will receive ABBV-547 Dose A.

Subcutaneous (SC) Injection

Eksperimentel: Substudy 3: ABBV-547 Dose B

Participants will receive ABBV-547 Dose B.

Subcutaneous (SC) Injection

Eksperimentel: Substudy 3: ABBV-547 Dose C

Participants will receive ABBV-547 Dose C.

Subcutaneous (SC) Injection

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Tidsramme: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

  1. ≥ 50% improvement in 68-tender joint count;

  2. ≥ 50% improvement in 66-swollen joint count; and

  3. ≥ 50% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Number of Participants With Adverse Events (AEs)
Tidsramme: Up to Week 52

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to Week 52

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Tidsramme: At Week 16

A participant was classified as achieving MDA if 5 of the following 7 criteria were met:

  • Tender joint count (out of 68 joints) ≤ 1
  • Swollen joint count (out of 66 joints) ≤ 1
  • PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3%
  • Participant's assessment of pain ≤ 1.5 (NRS from 0 to 10)
  • Participant's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10)
  • HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3)
  • Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
At Week 16
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Tidsramme: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

  1. ≥ 20% improvement in 68-tender joint count;

  2. ≥ 20% improvement in 66-swollen joint count; and

  3. ≥ 20% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Tidsramme: At Week 16

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:

  1. ≥ 70% improvement in 68-tender joint count;

  2. ≥ 70% improvement in 66-swollen joint count; and

  3. ≥ 70% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Tidsramme: At Week 16

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked).

The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

At Week 16

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: ABBVIE INC., AbbVie

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. april 2025

Primær færdiggørelse (Anslået)

1. august 2029

Studieafslutning (Anslået)

1. august 2029

Datoer for studieregistrering

Først indsendt

4. marts 2025

Først indsendt, der opfyldte QC-kriterier

4. marts 2025

Først opslået (Faktiske)

7. marts 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • M25-191
  • 2024-519291-11 (Substudy 1) (Anden identifikator: EU CT)
  • 2026-525937-21 (Substudy 2) (Anden identifikator: EU CT)
  • 2026-527719-41 (Substudy 3) (Anden identifikator: EU CT)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD-delingsadgangskriterier

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner